Ionis Pharmaceuticals (FRA:ISI) ROCE %: -10.58% (As of Mar. 2026)

What is Ionis Pharmaceuticals ROCE %?

Ionis Pharmaceuticals FRA:ISI +6.44% 65 ROCE % is -10.58% as of Mar. 2026. GuruFocus rates FRA:ISI with a GF Score™ of 65/100 and a GF Value™ of €47.81 (Significantly Overvalued). The stock has 8 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Ionis Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was -10.58%.

Ionis Pharmaceuticals (FRA:ISI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Ionis Pharmaceuticals ROCE % Related Terms

Ionis Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals ROCE % Chart

Ionis Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-1.23

-11.24

-10.46

-14.63

-10.26

Ionis Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-18.77	24.02	-20.28	-34.00	-10.58

65GF Score

Ionis Pharmaceuticals Inc FRA:ISI

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Ionis Pharmaceuticals ROCE % Calculation

Ionis Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-252.202	/	( ( (2868.51 - 295.399)	+	(3009.356 - 667.458) )	/ 2 )
	=	-252.202	/	( (2573.111	+	2341.898)	/ 2 )
	=	-252.202	/	2457.5045
	=	-10.26 %

Ionis Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-249.028	/	( ( (3009.356 - 667.458)	+	(2984.223 - 619.851) )	/ 2 )
	=	-249.028	/	( ( 2341.898	+	2364.372 )	/ 2 )
	=	-249.028	/	2353.135
	=	-10.58 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -10.58% mean?

Ionis Pharmaceuticals (FRA:ISI) has a ROCE % of -10.58% as of Mar. 2026.

Is Ionis Pharmaceuticals' ROCE % too high?

Ionis Pharmaceuticals' current ROCE % is -10.58%. Overall, Ionis Pharmaceuticals has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Ionis Pharmaceuticals' ROCE % compare to EXEL and BBIO?

Ionis Pharmaceuticals' ROCE % of -10.58% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. Ionis Pharmaceuticals's current ROCE % is -10.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Ionis Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Ionis Pharmaceuticals (FRA:ISI) is currently considered Significantly Overvalued. The stock's GF Value™ is €47.81, compared to a current price of €71.72 — trading 50% above its estimated fair value. The current ROCE % is -10.58%. Ionis Pharmaceuticals' overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Ionis Pharmaceuticals (FRA:ISI), the current ROCE % is -10.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (FRA:ISI) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of €71.72 is trading 50% above its estimated GF Value™ of €47.81. GuruFocus considers Ionis Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:ISI:

ROCE %: -10.58%
GF Value™: €47.81 vs. price of €71.72 (50% above fair value)
GF Score™: 65/100 with 8 warning signs

No single metric tells the full story. See the FRA:ISI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ionis Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies EXEL BBIO AXSM SMMT MDGL ASND BMRN ARWR JAZZ CYTK VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges IONS:USA 1IONS:Italy 0JDI:UK

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010

Website https://www.ionis.com

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

65GF Score

Get the complete analysis for FRA:ISI

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€71.72

Price

€47.81

GF Value

View FRA:ISI Analysis

See ROCE % data for all stocks →